(Q34698933)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Jason Konner

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

11

Alexia Iasonos

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

12

Paul Sabbatini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

5

Martee Hensley

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

6

Carol Aghajanian

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1

Douglas Levine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

3

Margrit Juretzka

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Julie Esch

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Sharyn Lewin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Felicia Derosa

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

David Spriggs

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

English

0 references

publication date

1 December 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

2448-2456

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17918264%20AND%20SRC:MED&resulttype=core&format=json

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Consolidation for ovarian cancer in remission

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Androgen receptor predominance in human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Endogenous Androgens and Risk of Epithelial Ovarian Cancer: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Review: gonadotropins and development of ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Gonadotropin-releasing hormone agonist suppression of ovarian tumorigenesis in mice of the Wx/Wv genotype.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Loss of ovarian function promotes angiogenesis in human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Multilocus analysis of SNP and metabolic data within a given pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

A New Statistical Method for Haplotype Reconstruction from Population Data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Use of tumour markers in monitoring the course of ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Second-line therapy of advanced ovarian cancer with GnRH analogs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021

When you look matters: the effect of assessment schedule on progression-free survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23072

7 January 2021